{"contentid": 488416, "importid": NaN, "name": "Hikma resumes launch of generic Advair Diskus in USA", "introduction": "London-listed Hikma Pharmaceuticals says it has resumed the launch of its generic version of GlaxoSmithKline\u00e2\u0080\u0099s Advair Diskus in the USA, following US Food and Drug Administration approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021.", "content": "<p>London-listed Hikma Pharmaceuticals (LSE: HIK) says it has resumed the launch of its generic version of GlaxoSmithKline&rsquo;s (LSE: GSK) Advair Diskus in the USA, following US Food and Drug Administration approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021.</p>\n<p><br /> The news saw Hikma&rsquo;s shares gain more than 3% to 2,451 pence by mid-afternoon trading today. The company has developed the copy of GSK&rsquo;s top-selling asthma treatment &nbsp;in partnership with Vectura (LSE: VEC), a leading inhalation contract development and manufacturing organization (CDMO), whose shares were also up more than 3% at 115.30 pence.</p>\n<p><br /> The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its abbreviated new drug application (ANDA).</p>\n<p>Hikma will immediately resume launch activities of its generic product for Advair Diskus (fluticasone propionate and salmeterol inhalation powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the USA.</p>\n<p>Siggi Olafsson, chief executive of Hikma, said: &ldquo;We appreciate the FDA&rsquo;s timely review and approval of our amendment and are now immediately resuming the launch of our high quality, substitutable generic version of Advair Diskus. We are very pleased to improve availability of this critical medicine for patients and healthcare providers in the US.&rdquo;</p>\n<h2><strong>Sales forecast</strong></h2>\n<p>Commenting on the news, Jefferies&rsquo; analyst James Vane-Tempest said: &ldquo;We had seen low risk to resumed launch, but expect this news to be viewed favourably and could see a relief rally given the delay to launch has been an overhang to the stock since Jan.&rdquo;</p>\n<p>He has forecast $34 million sales for Hikma's generic Advair in fiscal year 2021, which should be high margin and is a key contributor to his 21.8% FY21 US generics division adj earnings before interest and taxes (EBIT) margin, which is above consensus and guidance (Cons 20.2%; Guidance \"around 20% margin\").&nbsp;</p>", "date": "2021-04-21 14:12:00", "meta_title": "Hikma resumes launch of generic Advair Diskus in USA", "meta_keywords": "Hikma Pharmaceuticals, Launch Generic, Advair Diskus, USA, GlaxoSmithKline, Vectura", "meta_description": "Hikma resumes launch of generic Advair Diskus in USA", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-21 14:11:09", "updated": "2021-04-21 14:18:08", "access": NaN, "url": "https://www.thepharmaletter.com/article/hikma-resumes-launch-of-generic-advair-diskus-in-usa", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "hikma-big.jpg", "image2id": "hikma-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Generics", "therapy area_tag": "Respiratory and Pulmonary", "topic_tag": "Focus On, Product Launch, Regulation, US FDA", "geography_tag": "UK, USA", "company_tag": "GlaxoSmithKline, Hikma Pharmaceuticals, Vectura", "drug_tag": "Advair Diskus", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-21 14:12:00"}